Company news

Puma Biotechnology Inc news in 2024

Puma Biotechnology Inc's news releases, calls and decks from 2024, newest first.

View company

Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

December 22, 2024

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

November 19, 2024

Puma Biotechnology Reports Third Quarter 2024 Financial Results

November 6, 2024

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

June 2, 2024

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

June 1, 2024

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

May 22, 2024

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

March 19, 2024

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

February 28, 2024

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

February 12, 2024

Calls in 2024

Decks in 2024